Advent Life Sciences
Advent Life Sciences is a venture capital firm dedicated to investing in early-stage and growth equity life sciences companies across the UK, Europe, and the US. They focus on innovative sectors such as new drug discovery, med-tech, enabling technologies, and diagnostics. The firm supports its portfolio with a hands-on approach, working closely with management to bring innovative medicines and products to approval, with a history of successful investments and exits since 2006.
Industries
Nr. of Employees
small (1-50)
Advent Life Sciences
27 Fitzroy Square, London, W1T 6ES
Services
Direct provision of early and mid-stage capital to life sciences companies, typically from seed or Series A onward.
Hands-on support to refine scientific, clinical and business plans, recruit leadership and implement operating plans.
Structuring financing rounds, coordinating co-investors and managing milestone-based financing plans.
Strategic advice on regulatory pathways and commercialization planning to support market entry and approvals.
Direct provision of early and mid-stage capital to life sciences companies, typically from seed or Series A onward.
Hands-on support to refine scientific, clinical and business plans, recruit leadership and implement operating plans.
Structuring financing rounds, coordinating co-investors and managing milestone-based financing plans.
Strategic advice on regulatory pathways and commercialization planning to support market entry and approvals.
Expertise Areas
- Venture funding and syndication for life sciences
- Clinical development strategy and protocol planning
- Drug discovery across multiple modalities
- Medtech and device commercialization
Key Technologies
- Antibody discovery and display technologies including high-throughput screening and flow cytometry
- High-content cell-based screening
- Cardiac electrophysiology mapping technologies (contact and non-contact, 3D mapping and imaging)
- Catheter-based mapping systems for electrophysiology procedures
News & Updates
Acutus Medical’s new contact mapping software has received CE mark approval, marking a significant milestone for the company's innovative medical device technology.
Advent Life Sciences announced the appointment of Alain Huriez MD as a Venture Partner. Alain brings 22 years of experience in management, drug development, and financing in the life sciences sector, including leadership roles at TcLand Expression, Neovacs, Truffle Capital, and Quintiles.
Advent Life Sciences appointed Alain Huriez MD as Venture Partner, leveraging his extensive experience in management, drug development, and financing in the life sciences sector.
Acutus Medical’s new contact mapping software has received CE mark approval, marking a significant milestone for the company's innovative medical device technology.
Advent Life Sciences announced the appointment of Alain Huriez MD as a Venture Partner. Alain brings 22 years of experience in management, drug development, and financing in the life sciences sector, including leadership roles at TcLand Expression, Neovacs, Truffle Capital, and Quintiles.
Advent Life Sciences appointed Alain Huriez MD as Venture Partner, leveraging his extensive experience in management, drug development, and financing in the life sciences sector.